Literature DB >> 23524166

Identification of NF-κB Inhibitors in Xuebijing injection for sepsis treatment based on bioactivity-integrated UPLC-Q/TOF.

Min Jiang1, Mengge Zhou, Yanqi Han, Lu Xing, Hongzhi Zhao, Linyin Dong, Gang Bai, Guoan Luo.   

Abstract

ETHNOPHARMACOLOGICAL EVIDENCE: Inflammation plays an important role in sepsis, and NF-κB is a key mediator of inflammation. Xuebijing (XBJ) injection is a traditional Chinese medicine injection that was widely used in the treatment of sepsis in China. However, the active constituents and mechanism responsible for its actions have not been investigated experimentally. AIM OF THE STUDY: To screen the anti-inflammatory components in XBJ injection and investigate the modulation of NF-κB in the treatment of sepsis.
MATERIALS AND METHODS: In this study, the effect of XBJ was assessed in the cecal ligation and puncture (CLP) -induced sepsis model. Subsequently, a bioactivity-integrated ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-Q/TOF) assay system was established for screening potential anti-inflammatory ingredients in XBJ. Ultimately, six active ingredients were confirmed through an in vitro test.
RESULTS: XBJ significantly reduced the mortality rate, anal temperature and expression of TNF-α, IL-1β and IL-6 induced by CLP. Nine potential anti-inflammatory ingredients, including gallic acid, danshensu, protocatechualdehyde, hydroxysafflor yellow A, oxypaeoniflorin, paeoniflorin, safflor yellow A, senkyunolide I and benzoylpaeoniflorin, were found based on the bioactivity-integrated UPLC-Q/TOF assay system. Among these compounds, the NF-κB inhibitor activity of senkyunolide I, safflor yellow A, oxypaeoniflorin, and benzoylpaeoniflorin are first reported here.
CONCLUSIONS: XBJ showed significant efficacy in the treatment of sepsis induced by CLP. Multiple targets of the different components were related to these anti-inflammatory effects, which contributed to the treatment of sepsis by XBJ in a clinical setting.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23524166     DOI: 10.1016/j.jep.2013.03.032

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  43 in total

1.  Efficacy of Xuebijing Injection () on Cardiopulmonary Bypass-Associated Pulmonary Injury: A Prospective, Single-center, Randomized, Double Blinded Trial.

Authors:  Wei Gao; Na Li; Xiao-Guang Cui
Journal:  Chin J Integr Med       Date:  2018-07-31       Impact factor: 1.978

2.  Creation of a synthesis-friendly inflammation-inducible promoter suitable for cell therapy.

Authors:  Anish Jadav; Kevin Truong
Journal:  Integr Biol (Camb)       Date:  2021-10-15       Impact factor: 3.177

3.  Pharmacokinetics and disposition of monoterpene glycosides derived from Paeonia lactiflora roots (Chishao) after intravenous dosing of antiseptic XueBiJing injection in human subjects and rats.

Authors:  Chen Cheng; Jia-zhen Lin; Li Li; Jun-ling Yang; Wei-wei Jia; Yu-hong Huang; Fei-fei Du; Feng-qing Wang; Mei-juan Li; Yan-fen Li; Fang Xu; Na-ting Zhang; Olajide E Olaleye; Yan Sun; Jian Li; Chang-hai Sun; Gui-ping Zhang; Chuan Li
Journal:  Acta Pharmacol Sin       Date:  2016-02-01       Impact factor: 6.150

4.  Xuebijing injection for acute organophosphorus pesticide poisoning: a systematic review and meta-analysis.

Authors:  Po Huang; Bo Li; Shuo Feng; Yuhong Guo; Guozhen Zhao; Dongdong Wang; Qingquan Liu
Journal:  Ann Transl Med       Date:  2019-03

5.  Xuebijing attenuates decompression-induced lung injuries.

Authors:  Wen-Tao Meng; Long Qing; Quan Zhou; Wei-Gang Xu
Journal:  Diving Hyperb Med       Date:  2020-12-20       Impact factor: 0.887

6.  Paeoniflorin and Hydroxysafflor Yellow A in Xuebijing Injection Attenuate Sepsis-Induced Cardiac Dysfunction and Inhibit Proinflammatory Cytokine Production.

Authors:  Xin-Tong Wang; Zhen Peng; Ying-Ying An; Ting Shang; Guangxu Xiao; Shuang He; Xi Chen; Han Zhang; Yuefei Wang; Tao Wang; Jun-Hua Zhang; Xiumei Gao; Yan Zhu; Yuxin Feng
Journal:  Front Pharmacol       Date:  2021-04-13       Impact factor: 5.810

7.  Protecting Intestinal Microenvironment Alleviates Acute Graft-Versus-Host Disease.

Authors:  Zhengcan Zhou; Ting Shang; Xiurong Li; Hongyan Zhu; Yu-Bo Qi; Xin Zhao; Xi Chen; Zhe-Xin Shi; Guixiang Pan; Yue-Fei Wang; Guanwei Fan; Xiumei Gao; Yan Zhu; Yuxin Feng
Journal:  Front Physiol       Date:  2021-02-12       Impact factor: 4.566

8.  Xuebijing Ameliorates Sepsis-Induced Lung Injury by Downregulating HMGB1 and RAGE Expressions in Mice.

Authors:  Qiao Wang; Xin Wu; Xiaowen Tong; Zhiling Zhang; Bing Xu; Wugang Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2015-03-02       Impact factor: 2.629

9.  Xuebijing injection reduces organ injuries and improves survival by attenuating inflammatory responses and endothelial injury in heatstroke mice.

Authors:  Qiulin Xu; Jingxian Liu; Xiaohua Guo; Youqing Tang; Gengbiao Zhou; Yanan Liu; Qiaobing Huang; Yan Geng; Zhifeng Liu; Lei Su
Journal:  BMC Complement Altern Med       Date:  2015-02-05       Impact factor: 3.659

10.  Analysis of the Efficacy and Mechanism of Action of Xuebijing Injection on ARDS Using Meta-Analysis and Network Pharmacology.

Authors:  Yun Zhang; Jie Wang; Yong-Mei Liu; Hui Yang; Guang-Jun Wu; Xuan-Hui He
Journal:  Biomed Res Int       Date:  2021-05-22       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.